- $56.06m
- $38.98m
- $0.03m
Brief: Acelrx Pharmaceuticals Announces Publication Of Clinical Data Finding Potential Benefits Of Nafamostat Compared To Regional Citrate For Anticoagulation Of The Dialysis Circuit
AcelRx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: AcelRx Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results
AcelRx Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Announces Publication Of Clinical Data On Use Of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures
Brief: Acelrx Pharmaceuticals Announces Publication Of Clinical Data With Use Of Sublingual Sufentanil
Brief: AcelRx Pharmaceuticals Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
AcelRx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
AcelRx rises on deal to acquire Lowell, Q3 revenue jump
Brief: Acelrx Announces $14 Million Registered Direct Common Stock And Warrant Offering
Brief: AcelRx Pharmaceuticals To Acquire Lowell Therapeutics And Reports Third Quarter 2021 Financial Results
AcelRx Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview
AcelRx Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview
AcelRx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: AcelRx Pharmaceuticals Q2 Loss Per Share $0.08
AcelRx Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview
AcelRx Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview
AcelRx jumps on deal to commercialize opioid-based pain treatment in Europe
Brief: Acelrx Enters Into Licensing Agreement For DZUVEO In Europe